Literature DB >> 16088684

Long-term outcomes after ARDS.

C M Lee1, L D Hudson.   

Abstract

Early reports of late outcomes among survivors of ARDS indicated that most patients improved dramatically after their intensive care unit stay, and few lived with residua of their once-severe pulmonary injury. Over the last decade, a collection of new studies with improved methodology and novel questions has improved our understanding of life after ARDS. After reviewing these newer investigations in the context of previously published literature, we have drawn several preliminary conclusions: (1) Long-term survival after hospital discharge is unaffected by ARDS, but is strongly affected by ARDS risk factor and comorbidities. (2) Respiratory symptoms after ARDS are more prevalent than previously indicated, but improve over the first 12 months of recovery. (3) Pulmonary function testing reveals marked impairment soon after ARDS. There is improvement over the first 6 months, with lingering mild decreases in lung volume and diffusing capacity in most patients. A small group of patients have severe impairment without improvement. (4) Quality of life, functional independence, and cognitive function are severely affected by ARDS, with dramatic improvement over the first year. Quality of life is lower than in matched critically ill controls. (5) Significant numbers of ARDS survivors suffer from posttraumatic stress syndrome. This is an exciting time for research in long-term outcomes of ARDS, with potential for future studies that validate these single-center hypotheses, explore their ramifications, and investigate the impacts of changing practices in the intensive care unit in the acute phase of ARDS.

Entities:  

Year:  2001        PMID: 16088684     DOI: 10.1055/s-2001-15789

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  3 in total

1.  1-year pulmonary function and health status in survivors of severe acute respiratory syndrome.

Authors:  Kian-Chung Ong; Alan Wei-Keong Ng; Lawrence Soon-U Lee; Gregory Kaw; Seow-Khee Kwek; Melvin Khee-Shing Leow; Arul Earnest
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

2.  Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study.

Authors:  Helene Haeberle; Stefanie Prohaska; Peter Martus; Andreas Straub; Alexander Zarbock; Gernot Marx; Manola Zago; Martin Giera; Michael Koeppen; Peter Rosenberger
Journal:  Trials       Date:  2020-03-04       Impact factor: 2.279

3.  Impact of serum biomarkers and clinical factors on intensive care unit mortality and 6-month outcome in relatively healthy patients with severe pneumonia and acute respiratory distress syndrome.

Authors:  Chia-Cheng Tseng; Wen-Feng Fang; Sum-Yee Leung; Hung-Chen Chen; Ya-Chun Chang; Chin-Chou Wang; Huang-Chih Chang; Meng-Chih Lin
Journal:  Dis Markers       Date:  2014-03-03       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.